Echocardiographic effects of prostacyclin?

R. Day
DOI: https://doi.org/10.1161/01.CIR.97.9.940
IF: 37.8
1998-03-10
Circulation
Abstract:To the Editor: I read with interest the manuscript by Hinderliter and other members of the Primary Pulmonary Hypertension Study Group entitled “Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension.”1 I was disappointed that the authors stated conclusions with no supporting data. Previously, these authors reported that a 12-week continuous intravenous infusion of prostacyclin improved survival in patients with severe primary pulmonary hypertension.2 Hinderliter and associates now claim that a 12-week period of prostacyclin therapy also had important beneficial effects on right ventricular structure and function in this same group of patients. Unfortunately, the results were incompletely reported without appropriate statistical comparisons. The baseline echocardiographic features of treated patients and control subjects were well described. However, corresponding measurements, 12 weeks after randomization, were not reported. Furthermore, the authors reported none of the statistical comparisons between baseline and follow-up measurements. By comparing only the median differences between baseline and follow-up echocardiographic variables, the authors arrived at inappropriate and misleading conclusions. The median differences in most echocardiographic variables were so small that it is unlikely …
What problem does this paper attempt to address?